Organon & Co. (OGN) company profile
Close on Nov 16, 2026Market cap $3.65BP/E 18.1Yield 2.45%
About Organon
Pharmaceutical Preparations, SIC 2834
Organon & Co. is a healthcare company that develops and supplies pharmaceutical treatments centered on women’s health and general medicine. Its business is organized into women’s health, biosimilars, and established brands. The women’s health segment focuses on prescription contraception and fertility treatments, including implants, vaginal rings, and follicle-stimulating injections. Its biosimilar offerings treat immunology and oncology conditions, while the established brands portfolio covers cardiovascular, respiratory, dermatology, bone health, and non-opioid pain medications. Organon distributes its products to drug wholesalers, retailers, hospitals, government agencies, and managed care institutions such as pharmacy benefit managers and health maintenance organizations.
The company distributes medications across more than 140 countries and territories, with its women’s health offerings available in over 90 international markets. It operates six manufacturing facilities situated in Belgium, Brazil, Indonesia, Mexico, the Netherlands, and the United Kingdom. Organon employs over 10,000 people globally, with around 1,500 workers located in the United States and Puerto Rico. The provided text does not state the company's headquarters.
Summary of the business section of Organon's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Organon & Co.
- Founded
- 1923
- Headquarters
- Jersey City, NJ
- Address
- 30 Hudson Street, Fl 33 07302
- Phone
- (551) 430-6000
- Website
- www.organon.com
- Employees
- 10,000, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, Florham Park, New Jersey
Stock & identifiers
- Ticker
- OGN
- Exchange
- NYSE
- IPO date
- May 14, 2021
- Shares outstanding
- 263M, Oct 23, 2026
- Public float
- $2.50B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1821825
- CUSIP
- 68622V106
- ISIN
- US68622V1061
- FIGI
- BBG00ZQRGW24
- Share class FIGI
- BBG00ZQRGW42
- LEI
- 549300AMCKY57OK2CO56
- EIN
- 46-4838035
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Carrie Smith Cox | Executive Chair, Director | 90,338 |
| Kevin Ali | Chief Executive Officer, Director | 282,731 |
| Juliana Papa Drinane | Head of Mfg & Supply | 35,239 |
| Joseph T. Morrissey Jr. | CEO | 153,316 |
| Ferreira Juan Camilo Arjona | Head of R&D & CMO | 41,565 |
| Lynette Holzbaur | SVP and Corporate Controller | 3,901 |
| Vittorio Nisita | Head of Global Business Svcs | 70,619 |
| Rachel A. Stahler | Chief Information Officer | 110,256 |
| Matthew M. Walsh | Chief Financial Officer | 202,707 |
| Kirke Weaver | Gen. Counsel & Corp. Secy. | 85,602 |
| Daniel Karp | Executive VP, Corp. Dev. | 71,653 |
| Aaron Falcione | Chief Human Resources Officer | 96,378 |
| Kathryn DiMarco | Corporate Controller | 35,917 |
| Alan Ezekowitz | Director | – |
| Shalini Sharp | Director | 2 |
| Cynthia M. Patton | Director | – |
| Ramona Sequeira | Director | 100 |
| Deborah R. Leone | Director | 10 |
| Philip Ozuah | Director | – |
| Robert Essner | Director | – |
| Rochelle B. Lazarus | Director | 633 |
| Helene D. Gayle | Director | – |
| Grace Puma Whiteford | Director | 5 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Joseph Morrissey | $5.77M | $2.73M | $4.15M | $2368 | $15636 |
| FY2025 Kevin Ali | $15.81M | -$9.84M | $4.15M | $2368 | $15636 |
| FY2024 | $17.12M | $16.38M | $4.42M | $4805 | $12975 |
| FY2023 | $14.83M | -$553.77K | $4.07M | $4371 | $12639 |
| FY2022 | $13.53M | $11.73M | $4.13M | $7965 | $12052 |
| FY2021 | $18.55M | $14.26M | $5.31M | $8372 | $11488 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Joseph Morrissey Interim Chief Executive Officer | $819.23K | $3.37M | $750.00K | $602.43K | $235.37K | $5.77M | +40% |
| Matthew Walsh EVP and Chief Financial Officer | $919.23K | $3.04M | $962.50K | $532.80K | $235.50K | $5.69M | -1% |
| Juan Camilo Arjona Ferreira, M.D. EVP and Head of R&D and Chief Medical Officer | $734.62K | $1.89M | $600.00K | $437.76K | $157.46K | $3.82M | +6% |
| Rachel Stahler EVP and Chief Digital & Growth Officer | $706.92K | $1.73M | $550.00K | $411.84K | $147.92K | $3.55M | – |
| Kirke Weaver EVP, General Counsel and Corporate Secretary | $676.92K | $1.73M | $550.00K | $394.56K | $186.56K | $3.54M | +1% |
| Kevin Ali Former Chief Executive Officer | $1.09M | $10.25M | $3.25M | – | $1.22M | $15.81M | -8% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had over 10,000 employees worldwide with approximately 1,500 (15%) employees in the United States, including Puerto Rico.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jun 17, 2026 | Merger vote | Definitive merger proxy statement |
| Jun 3, 2021 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Mar 17, 2021 | Spin-off | Registration as a new public company (Form 10), e.g. spin-off |
See a number that looks wrong?